What Else Can Dostarlimab Treat
The trial was small—it involved just 18 people and only 12 completed the treatment—but the results were exciting. The researchers found that, after taking dostarlimab every three weeks for six months, all patients with mismatch repair-deficient stage II or III rectal adenocarcinoma had “no evidence of tumor” on MRI or other tests. “At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up,” which was between six to 25 months, the researchers wrote....